



June 21, 2021

PRESS RELEASE

Company: RaQualia Pharma Inc.  
(Securities code: 4579)

Representative: President & CEO Hirobumi Takeuchi  
Contact: Director, Business Strategy Masaki Sudo  
(Phone +81-52-446-6100)

## **Ghrelin Receptor Agonist (Serine Derivative) Patent Allowance in China**

RaQualia Pharma Inc. (RaQualia) today announced that the company has received an allowance\* for a ghrelin receptor agonist substance patent in China (Application number: 201580025740.3). This patent allowance ensures that RaQualia's intellectual property rights for this compound will be strengthened at all five major patent offices: Japan, the United States, Europe, China and Korea.

Ghrelin is a peptide hormone mainly secreted from the stomach. The hormone is known to enhance the secretion of growth hormone, increase appetite, and promote gastrointestinal motility.

RaQualia's ghrelin receptor agonist is a small molecule compound that can be orally administered. Acting at ghrelin receptors, the compound exhibits various effects in animal models such as improvement of anorexia, suppression of weight loss, and promotion of gastrointestinal motility. RaQualia expects that the compound will be a breakthrough drug in maintaining and improving the quality of life (QOL) of patients.

RaQualia will continue to strengthen its intellectual property portfolio and strive for licensing activities.

The financial forecasts for the fiscal year 2021 (Jan. 1, 2021 – Dec. 31, 2021) will not be affected by this announcement.

### **About patent allowance:**

Patent allowance is issued by each country's patent office to recognize an applied invention as "an invention worthy of a patent." After the patent fee is paid, the patent will be registered in the relevant country.